Drug Approval | March 06, 2022
USFDA approves expanded use of Bristol Myers Opdivo
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
To mark International HPV Awareness Day on March 4th 2022, the International Papillomavirus Society (IPVS) has warmly welcomed two major advances in the elimination of cervical and anal cancers
Ten new Ayush hospitals and one Ayurvedic college will be set up in Nagaland and Mizoram
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant
Subscribe To Our Newsletter & Stay Updated
